Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy

被引:3
作者
Mathis, Stephane [1 ]
Vallat, Jean-Michel [2 ]
Magy, Laurent [2 ]
机构
[1] Univ Hosp Poitiers, Dept Neurol, 2 Rue Miletrie, F-86021 Poitiers, France
[2] Univ Hosp Limoges, Ctr Reference Neuropathies Peripher, Dept Neurol, 2 Ave Martin Luther King, F-87042 Limoges, France
关键词
chronic inflammatory demyelinating polyneuropathy; CIDP; corticosteroids; immunomodulation; immunosuppressant; intravenous immunoglobulin; IVIg; plasma exchange; INTRAVENOUS IMMUNOGLOBULIN TREATMENT; HIGH-DOSE CYCLOPHOSPHAMIDE; STEM-CELL TRANSPLANTATION; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED TRIAL; REGULATORY T-CELLS; PLASMA-EXCHANGE; DOUBLE-BLIND; SUBCUTANEOUS IMMUNOGLOBULIN; POLYRADICULONEUROPATHY CIDP;
D O I
10.2217/imt.15.107
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic immune-mediated neuropathy: it is clinically heterogeneous (relapsing-remitting form, chronic progressive form, monophasic form or CIDP having a Guillain-Barre syndrome-like onset), but potentially treatable. Although its pathophysiology remains largely unknown, CIDP is considered an immune-mediated neuropathy. Therefore, many immunotherapies have been proposed in this peripheral nervous system disorder, the most known efficient treatments being intravenous immunoglobulin, corticosteroids and plasma exchange. However, these therapies remain unsatisfactory for many patients, so numerous other immunotherapeutic strategies have been evaluated, based on their immunosuppressant or immunomodulatory potency. We have performed a large review of the literature about treatment in CIDP, with a special emphasis on novel and alternative immunotherapeutic strategies.
引用
收藏
页码:165 / 178
页数:14
相关论文
共 121 条
[1]   Positive effects of tacrolimus in a case of CIDP [J].
Ahlmén, J ;
Andersen, O ;
Hallgren, G ;
Peilot, B .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (08) :4194-4194
[2]   CIDP diagnostic pitfalls and perception of treatment benefit [J].
Allen, Jeffrey A. ;
Lewis, Richard A. .
NEUROLOGY, 2015, 85 (06) :498-504
[3]  
[Anonymous], COCHRANE DATABASE SY
[4]   Immunoadsorption in patients with autoimmune ion channel disorders of the peripheral nervous system [J].
Antozzi, Carlo .
ATHEROSCLEROSIS SUPPLEMENTS, 2013, 14 (01) :219-222
[5]   Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP [J].
Axelson, H. W. ;
Oberg, G. ;
Askmark, H. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2008, 79 (05) :612-+
[6]  
Barnett MH, 1998, MUSCLE NERVE, V21, P454, DOI 10.1002/(SICI)1097-4598(199804)21:4<454::AID-MUS3>3.3.CO
[7]  
2-E
[8]   Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature [J].
Benedetti, L. ;
Briani, C. ;
Franciotta, D. ;
Fazio, R. ;
Paolasso, I. ;
Comi, C. ;
Luigetti, M. ;
Sabatelli, M. ;
Giannini, F. ;
Mancardi, G. L. ;
Schenone, A. ;
Nobile-Orazio, E. ;
Cocito, D. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2011, 82 (03) :306-308
[9]   CURRENT TREATMENTS OF CHRONIC IMMUNE-MEDIATED DEMYELINATING POLYNEUROPATHIES [J].
Brannagan, Thomas H., III .
MUSCLE & NERVE, 2009, 39 (05) :563-578
[10]   Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy [J].
Breiner, Ari ;
Brannagan, Thomas H., III .
MUSCLE & NERVE, 2014, 50 (01) :40-46